Robin K Dore

Summary

Country: USA

Publications

  1. doi request reprint How to prevent glucocorticoid-induced osteoporosis
    Robin K Dore
    David Geffen School of Medicine at UCLA, Tustin, CA 92780, USA
    Cleve Clin J Med 77:529-36. 2010
  2. doi request reprint Data from extension trials: denosumab and zoledronic acid
    Robin K Dore
    David Geffen School of Medicine, Division of Rheumatology, UCLA, 18102 Irvine Blvd Suite 104, Tustin, CA 92780, USA
    Curr Osteoporos Rep 10:16-21. 2012
  3. doi request reprint Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
    Robin K Dore
    Robin K Dore Inc, Tustin, CA, USA
    Ann Rheum Dis 69:872-5. 2010
  4. doi request reprint Patient experience with a new teriparatide delivery device
    Robin K Dore
    Robin K Dore MD, Inc, 18102 Irvine Boulevard, Suite 104, Tustin, CA 92780 3423, USA
    Curr Med Res Opin 25:2413-22. 2009
  5. doi request reprint Gout: what primary care physicians want to know
    Robin K Dore
    Division of Rheumatology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095 1720, USA
    J Clin Rheumatol 14:S47-54. 2008
  6. ncbi request reprint The gout diagnosis
    Robin K Dore
    Division of Rheumatology, David Geffen School of Medicine, University of California at Los Angeles, 92780, USA
    Cleve Clin J Med 75:S17-21. 2008
  7. ncbi request reprint The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis
    R K Dore
    Robin K Dore, MD, Inc, Anaheim, CA 92801, USA
    Clin Exp Rheumatol 25:40-6. 2007
  8. ncbi request reprint Reduced risk of back pain following teriparatide treatment: a meta-analysis
    Michael C Nevitt
    University of California San Francisco, San Francisco, CA, USA
    Osteoporos Int 17:273-80. 2006
  9. doi request reprint The RANKL pathway and denosumab
    Robin K Dore
    Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Rheum Dis Clin North Am 37:433-52, vi-vii. 2011
  10. doi request reprint American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
    Kenneth G Saag
    University of Alabama, Birmingham, AL, USA
    Arthritis Rheum 59:762-84. 2008

Detail Information

Publications12

  1. doi request reprint How to prevent glucocorticoid-induced osteoporosis
    Robin K Dore
    David Geffen School of Medicine at UCLA, Tustin, CA 92780, USA
    Cleve Clin J Med 77:529-36. 2010
    ..When prescribing glucocorticoids for long-term treatment, physicians should take steps to prevent osteoporosis, a common and serious side effect of these drugs...
  2. doi request reprint Data from extension trials: denosumab and zoledronic acid
    Robin K Dore
    David Geffen School of Medicine, Division of Rheumatology, UCLA, 18102 Irvine Blvd Suite 104, Tustin, CA 92780, USA
    Curr Osteoporos Rep 10:16-21. 2012
    ..As treatment of osteoporosis may extend for many years, the collection of long-term efficacy and safety data is warranted. This paper discusses data from the extension trials of denosumab and zoledronic acid...
  3. doi request reprint Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
    Robin K Dore
    Robin K Dore Inc, Tustin, CA, USA
    Ann Rheum Dis 69:872-5. 2010
    ....
  4. doi request reprint Patient experience with a new teriparatide delivery device
    Robin K Dore
    Robin K Dore MD, Inc, 18102 Irvine Boulevard, Suite 104, Tustin, CA 92780 3423, USA
    Curr Med Res Opin 25:2413-22. 2009
    ..To determine functionality and acceptability of a new teriparatide (Forteo, Eli Lilly and Company, Indianapolis, IN, USA) delivery device by patients with osteoporosis...
  5. doi request reprint Gout: what primary care physicians want to know
    Robin K Dore
    Division of Rheumatology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095 1720, USA
    J Clin Rheumatol 14:S47-54. 2008
    ..It also highlights the importance of providing practical recommendations to PCPs to improve the standard of care for gout in the primary care setting...
  6. ncbi request reprint The gout diagnosis
    Robin K Dore
    Division of Rheumatology, David Geffen School of Medicine, University of California at Los Angeles, 92780, USA
    Cleve Clin J Med 75:S17-21. 2008
    ..A thorough patient history and physical examination are critical to a presumptive diagnosis of gout, as is serum urate measurement at the time of an acute attack and at follow-up 2 weeks later...
  7. ncbi request reprint The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis
    R K Dore
    Robin K Dore, MD, Inc, Anaheim, CA 92801, USA
    Clin Exp Rheumatol 25:40-6. 2007
    ..To evaluate the immunogenicity, safety, and efficacy of 50 mg/mL liquid etanercept...
  8. ncbi request reprint Reduced risk of back pain following teriparatide treatment: a meta-analysis
    Michael C Nevitt
    University of California San Francisco, San Francisco, CA, USA
    Osteoporos Int 17:273-80. 2006
    ..In conclusion, patients randomized to teriparatide had a reduced risk of new or worsening back pain compared to patients randomized to placebo, hormone replacement therapy or alendronate...
  9. doi request reprint The RANKL pathway and denosumab
    Robin K Dore
    Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Rheum Dis Clin North Am 37:433-52, vi-vii. 2011
    ..It is the first biologic antiresorptive therapy for osteoporosis, and the first osteoporosis therapy to show efficacy and safety in patients with renal impairment...
  10. doi request reprint American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
    Kenneth G Saag
    University of Alabama, Birmingham, AL, USA
    Arthritis Rheum 59:762-84. 2008
  11. doi request reprint Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial
    Stanley B Cohen
    Metroplex Clinical Research Center, Dallas, Texas 75235, USA
    Arthritis Rheum 58:1299-309. 2008
    ..The aim of this multicenter, randomized, double-blind, placebo-controlled, phase II study was to evaluate the effects of denosumab on structural damage in patients with rheumatoid arthritis (RA) receiving methotrexate treatment...
  12. ncbi request reprint A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
    Jean Jacques Body
    Department of Medicine, Institut J Bordet, Universite Libre de Bruxelles, 1000 Brussels, Belgium
    J Clin Endocrinol Metab 87:4528-35. 2002
    ..In conclusion, teriparatide, a bone formation agent, increased BMD at most sites and decreased nonvertebral fractures more than alendronate...